PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
Status:
Withdrawn
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety of PD-1 knockout engineered T cells in treating
castration resistant prostate cancer (CRPC). Blood samples will also be collected for
research purposes.